Pacific Biosciences Of California (PACB) Accounts Payables (2010 - 2026)

Pacific Biosciences Of California has reported Accounts Payables for 17 years, with the latest figure at $19.2 million in Q2 2026.

• On a quarterly basis, Accounts Payables rose 27.69% year-over-year to $19.2 million in Q2 2026; TTM through Jun 2026 was $19.2 million, a 27.69% increase from a year earlier, with the FY2025 full-year figure at $20.8 million, up 25.2% from the prior year.
• Accounts Payables was $19.2 million for Q2 2026 at Pacific Biosciences Of California, up from $13.6 million in the prior quarter.
• The five-year high for Accounts Payables was $21.0 million in Q1 2024, with the low at $12.0 million in Q4 2022.
• Average Accounts Payables over 5 years is $15.9 million, with a median of $16.2 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables soared 407.26% in 2022, then sank 33.18% in 2025.
• Over 5 years, Accounts Payables stood at $12.0 million in 2022, then climbed by 25.22% to $15.1 million in 2023, then gained by 10.14% to $16.6 million in 2024, then increased by 25.2% to $20.8 million in 2025, then fell by 7.44% to $19.2 million in 2026.
• The last three Accounts Payables figures came in at $19.2 million (Q2 2026), $13.6 million (Q1 2026), and $20.8 million (Q4 2025), per Business Quant data.